stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) EPS (diluted)
Viridian Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$3.32, compared with −$3.07 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.37. Over the past ten years it has ranged from −$421.79 (fiscal 2016) to −$3.07 (fiscal 2024); the current reading is higher than 91% of that period. Viridian Therapeutics, Inc. ranks 394th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.32 | — |
| FY2024 | −$3.07 | — |
| FY2023 | −$5.31 | — |
| FY2022 | −$4.05 | — |
| FY2021 | −$6.68 | — |
| FY2020 | −$31.13 | — |
| FY2019 | −$20.09 | — |
| FY2018 | −$16.49 | — |
| FY2017 | −$20.69 | — |
| FY2016 | −$421.79 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.05 | — |
| Mar 2026 | −$0.90 | — |
| Dec 2025 | −$1.08 | — |
| Sep 2025 | −$0.34 | — |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | −$1.67 |
| DNLI Denali Therapeutics Inc. compare | −$1.73 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| VRDN Viridian Therapeutics, Inc. | −$3.37 |
| CELC Celcuity, Inc. compare | −$4.30 |
| IDYA IDEAYA Biosciences, Inc. compare | −$4.49 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$15.19 |
| TLX Telix Pharmaceuticals Limited compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on VRDN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement